A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
VIEW TRIAL ON CLINICALTRIALS.GOVBiliary Tract, cholangiocarcinoma, gallbladder cancer, bile duct cancer
Stage 4
Phase 3
Open to Enrollment
1st Line
nab-paclitaxel
taxane
Axel Grothey, MD
Southwest Oncology Group (SWOG)
biliary carcinoma
A Multicenter, Open-label Phase 2 Study of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) in Previously Treated Subjects with Selected Solid Tumors (LEAP-005)
VIEW TRIAL ON CLINICALTRIALS.GOVBiliary Tract Cancer, Cholangiocarcinoma; Gallbladder cancer
Stage 4
Phase 2
Open to Enrollment
2nd Line
Lenvatinib and Pembrolizumab
VEGF-R/FGFR inhibitor and PD-1 inhibitor
Manjari Pandey, MD
Merck Sharp & Dohme Corp
Adenocarcinoma
A Randomized Phase II Trial of Atezolizumab With or Without Bevacizumab in Cisplatin-ineligible Patients With Advanced/Unresectable Urothelial Cancer: Hoosier Cancer Research Network GU15-215
VIEW TRIAL ON CLINICALTRIALS.GOVBladder, Transitional Cell, Ureter, Urethral, Renal Pelvis, Urothelial
Stage 4
Phase 2
Open to Enrollment
1st Line
Atezolizumab and Bevacizumab
PD-L1 Antibody; VEGFR Antibody
Dan Vaena, MD
Hoosier Cancer Research Network
Transitional Cell Carcinoma
A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab in Combination With Standard of Care Chemotherapy and Durvalumab in Combination With Tremelimumab and Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone in Patients With Unresectable Locally Advanced or Metastatic Urothelial Cancer
VIEW TRIAL ON CLINICALTRIALS.GOVBladder Cancer, Urothelial Cancer, Transitional Cell Carcinoma, Ureter, Renal Pelvis
Stage 4
Phase 3
Open to Enrollment
1st Line
Durvalumab, Tremelimumab
PD-L1 antibody, CTLA-4 antibody
Dan Vaena, MD
AstraZeneca
Transitional cell carcinoma
Randomized phase II trial of preoperative fulvestrant with or without enzalutamide in ER+/HER2- breast cancer
VIEW TRIAL ON CLINICALTRIALS.GOVBreast cancer, Hormone receptor positive breast cancer, locally advanced BC
Stage 2
Phase 2
Open to Enrollment
N/A
Enzalutamide and fulvestrant
Androgen receptor inhibitor
Greg Vidal, MD, PhD
University of Colorado, Department of Defense
ER positive, HER2 negative
Phase II Trial Evaluating the Efficacy and Safety of Neoadjuvant Neratinib and Chemotherapy in Early Stage Triple-Negative Breast Cancer Patients Who Exhibit Enhanced HER2 Signaling by Live Cell HER2 Signaling Transduction Analysis (FACT-2)
VIEW TRIAL ON CLINICALTRIALS.GOVBreast, Triple Negative Breast Cancer
Stage 2
Phase 2
Open to Enrollment
Neoadjuvant
Neratinib
HER2 targeted small molecule
Greg Vidal, MD, PhD
West Cancer Center, Puma Biotechnology, Celcuity
ER negative, PR negative, HER2 negative
RT CHARM: Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation With Breast Reconstruction
VIEW TRIAL ON CLINICALTRIALS.GOVBreast cancer
Stage 2
Phase 3
Open to Enrollment
Adjuvant
Hypofractionated radiotherapy
Radiation
Noam VanderWalde, MD
Alliance for Clinical Trials in Oncology
Invasive ductal, invasive lobular, tubular
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
VIEW TRIAL ON CLINICALTRIALS.GOVBreast Cancer, Early Breast Cancer, Node-positive breast cancer
Stage 2
Phase 3
Open to Enrollment
Post-neoadjuvant
N/A
N/A
Richard Fine, MD
Alliance for Clinical Trials in Oncology
Node-positive any histology
Breast Cancer, Early Breast Cancer, Node-positive breast cancer
Stage 2
Phase 3
Open to enrollment
Post-neoadjuvant
regional nodal irradiation
N/A
Noam VanderWalde, MD
NSABP Foundation
Node positive prior to surgery, pathologically node negative at surgery
Patients must have pathologic confirmation of axillary nodal involvement at presentation (before neoadjuvant therapy) based on a positive FNA (demonstrating malignant cells) or positive core needle biopsy (demonstrating invasive adenocarcinoma). Patients may not have had documentation of axillary nodal positivity by sentinel node biopsy (before neoadjuvant therapy).
Patient must have clinically T1-3, N1 breast cancer at the time of diagnosis (before neoadjuvant chemotherapy)
Hormone receptor status must be performed on the primary breast tumor before neoadjuvant chemotherapy.
HER2 status must be performed on the primary breast tumor before neoadjuvant chemotherapy. Patients who have a primary tumor that is either HER2-positive or HER2-negative are eligible)
Patients must have completed a minimum of 8 weeks of standard neoadjuvant chemoterahyp consisting of an anthracycline and/or taxane-based regimen
For patients who receive adjuvant chemotherapy after surgery a maximum of 12 weeks of intended chemotherapy may be administered but must be completed before randomization
Patients with HER2-positive tumors must have received neoadjuvant anti-HER2 therapy (with all or with a portion of the neoadjuvant chemotherapy regimen), unless medically contraindicated.
At the time of definitive surgery, all removed axillary nodes must be histologically free of cancer
ECOG PS 0-1
A Phase III Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of GDC-9545 Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Patients With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
VIEW TRIAL ON CLINICALTRIALS.GOVBreast cancer
Stage 4
Phase 3
Open to Enrollment
1st line (pre-chemo)
GDC-9545
Selective estrogen receptor degrader (SERD)
Greg Vidal, MD, PhD
Hoffmann-LaRoche
ER+ (positive), HER2 - (negative)
A Phase 1 Study of MK-5890 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
VIEW TRIAL ON CLINICALTRIALS.GOVBreast, Triple Negative Breast Cancer, TNBC
Stage 4
Phase 1
Open to Enrollment
2nd or 3rd line
MK-5890
CD27 agonist
Dan Vaena, MD
Merck Sharp & Dohme Corp
ER negative, PR negative, HER2 negative
An Open-Label, Randomized, Multicenter Study Evaluating the Activity of Lasofoxifene Relative to Fulvestrant for the Treatment of Postmenopausal Women With Locally Advanced or Metastatic ER+/HER2− Breast Cancer With an ESR1 Mutation
VIEW TRIAL ON CLINICALTRIALS.GOVBreast cancer, invasive breast cancer, BC, hormone receptor positive BC
Stage 4
Phase 2
Open to Enrollment
2nd Line or later endocrine tx
Lasofoxifene
SERM
Lee Schwartzberg, MD
Sermonix Pharmaceuticals LLC
ER positive, HER2 negative
A Multicenter, Phase 2 Study of Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Metastatic TNBC and Tesetaxel Monotherapy in Elderly Patients With HER2 Negative MBC
VIEW TRIAL ON CLINICALTRIALS.GOVBreast cancer, triple-negative breast cancer, TNBC
Stage 4
Phase 2
Open to Enrollment
1st Line
Tesetaxel, nivolumab, pembrolizumab, atezolizumab
oral taxane, PD-1 or PD-L1 inhibitors
Lee Schwartzberg, MD
Odonate Therapeutics, Inc.
ER negative, PR negative, HER2 negative
A Phase 1b/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy And Safety Of Multiple Immunotherapy-Based Treatment Combinations In Patients With Metastatic Triple-Negative Breast Cancer
VIEW TRIAL ON CLINICALTRIALS.GOVBreast, Triple Negative Breast Cancer, TNBC
Stage 4
Phase 1
Open to Enrollment
2nd Line
Atezolizumab with Ipatasertib or ladiratuzumab-vidotin or Bevacizumab or Cobimetinib or Capecitabine or Combination Chemo
PD-L1 antibody with either PI3Ki or LIV1A ADC or MEKi or VEGFRi or chemo
Greg Vidal, MD, PhD
Hoffman-La Roche
ER- (negative), PR- (negative), HER2- (negative)
An open-label, multicenter, randomized Phase 3 study of first-line encorafenib plus cetuximab with or without chemotherapy versus standard of care therapy with a safety lead-in of encorafenib and cetuximab plus chemotherapy in participants with metastatic BRAF V600E-mutant colorectal cancer
VIEW TRIAL ON CLINICALTRIALS.GOVColon, Rectum, Colorectal
Stage 4
Phase 3
Open to Enrollment
Encorafenib, cetuximab
BRAF inhibitor, EGFR antibody
Axel Grothey, MD
Pfizer
A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Olaparib Alone or in Combination With Bevacizumab Compared to Bevacizumab With 5-FU in Participants With Unresectable or Metastatic Colorectal Cancer Who Have Not Progressed Following First-line Induction of FOLFOX With Bevacizumab (LYNK-003)
VIEW TRIAL ON CLINICALTRIALS.GOVColon, Rectal, Colorectal
Stage 4
Phase 3
Open to Enrollment
Maintenance (after 1st Line)
Olaparib + Bevacizumab
PARP inhibitor
Axel Grothey, MD
Merck Sharp & Dohme Corp
Adenocarcinoma
A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination with Durvalumab Followed by Maintenance Durvalumab with or without Olaparib in Patients with Newly Diagnosed Advanced or Recurrent Endometrial Cancer (DUO-E)
VIEW TRIAL ON CLINICALTRIALS.GOVEndometrial cancer, uterine cancer
Stage 4
Phase 3
Open to Enrollment
1st Line + maintenance
Durvalumab + olaparib
PD-L1 inhibitor, PARP inhibitor
Adam ElNaggar, MD
AstraZeneca
Epithelial endometrial carcinoma, carcinosarcoma
A Multicenter, Open-label Phase 2 Study of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) in Previously Treated Subjects with Selected Solid Tumors (LEAP-005)
VIEW TRIAL ON CLINICALTRIALS.GOVGlioblastoma Multiforme, GBM, malignant glioma
Stage 4
Phase 2
Open to Enrollment
2nd Line
Lenvatinib and Pembrolizumab
VEGF-R/FGFR inhibitor and PD-1 inhibitor
Manjari Pandey, MD
Merck Sharp & Dohme Corp
GBM
A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
VIEW TRIAL ON CLINICALTRIALS.GOVHead and Neck, Oropharyx, Oropharyngeal cancer
Stage 3
Phase 3
Open to Enrollment
N/A
Reduced dose radiation with chemo or IO
XRT
Noam VanderWalde, MD
NRG Oncology
HPV positive (+)
A Phase 1/2 Study of BMS-986315 as Monotherapy and in Combination with Nivolumab or
Cetuximab in Participants with Advanced Solid Tumors
Head and neck cancer (SCCHN), laryngeal, hypopharyngeal, oropharyngeal, oral cavity, oropharynx, hypopharynx, larynx
Stage 4
Phase 1
Open to Enrollment
> or = 2nd line
BMS-986315 with either nivolumab or cetuximab
NKG2A inhibitor
Dan Vaena, MD
Bristol-Myers Squibb
squamous cell carcinoma
Phase 1/1b Study of the Safety of TTX-030 as a Single Agent and in Combination With Pembrolizumab or Chemotherapy in Patients With Lymphoma or Solid Tumor Malignancies
VIEW TRIAL ON CLINICALTRIALS.GOVHead and Neck (SCCHN), laryngeal, hypopharyngeal, oropharyngeal, oral cavity, hypopharynx, larynx, oropharynx
Stage 4
Phase 1
Open to Enrollment
Any line as long as appropriate to give study acceptable chemo in combination
TTX-030
anti CD-39
Dan Vaena, MD
Trishula Therapeutics, Inc.
squamous cell carcinoma
A Phase 3 Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First-line Intervention in Participants With Metastatic Nonsquamous Non-small Cell Lung Cancer (LEAP-006)
VIEW TRIAL ON CLINICALTRIALS.GOVLung cancer, Non-small cell lung cancer, NSCLC
Stage 4
Phase 3
Open to Enrollment
1st Line
Lenvatinib and Pembrolizumab
VGFR antibody, PD-1 antibody
Ari VanderWalde, MD
Merck Sharp & Dohme Corp
Adenocarcinoma, large-cell carcinoma, broncho-alveolar carcinoma
A Phase 1 Study of MK-5890 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
VIEW TRIAL ON CLINICALTRIALS.GOVLung cancer, non-squamous lung cancer, NSCLC
Stage 4
Phase 1
Open to Enrollment
1st Line (or 2nd line in rare cases)
MK-5890
CD27 agonist
Dan Vaena, MD
Merck Sharp & Dohme Corp
Adenocarcinoma, large-cell carcinoma, broncho-alveolar carcinoma
Pivotal, open-label, randomized study of radiosurgery with or without tumor treating fields (TTFields) for 1-10 brain metastases from non-small cell lung cancer (NSCLC)
VIEW TRIAL ON CLINICALTRIALS.GOVLung Cancer; NSCLC, non-small cell lung cancer; brain metastases
Stage 4
Phase 3
Open to Enrollment
N/A
NovoCure TTFields
Device administering alternating electrical fields
Matt Ballo, M.D.
NovoCure Ltd.
Non-small cell lung cancer. EGFR wt, ALK/ROS normal
A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma: Substudy 02C
VIEW TRIAL ON CLINICALTRIALS.GOVMelanoma, Cutaneous Melanoma
Stage 3
Phase 2
Open to Enrollment
Neoadjuvant
Pembrolizumab, MK-7684, V937
Anti-PD-1, Anti-TIGIT, Oncolytic virus
David Portnoy, MD
Merck Sharp & Dohme Corp
Melanoma
A Phase 1/2 open-lable rolling-arm umbrella platford design of investigational agents with or without pembrolizumab or pembrolizumab alone in participants with melanoma (KEYNOTE-U02): Substudy 02B.
VIEW TRIAL ON CLINICALTRIALS.GOVMelanoma, Cutaneous Melanoma
Stage 4
Phase 2
Open to Enrollment
1st Line, PD-1 naive
Multiple
David Portnoy, MD
Merck Sharp & Dohme Corp
Melanoma
A Phase 1/2 open-lable rolling-arm umbrella platford design of investigational agents with or without pembrolizumab or pembrolizumab alone in participants with melanoma (KEYNOTE-U02): Substudy 02A.
VIEW TRIAL ON CLINICALTRIALS.GOVMelanoma
Stage 4
Phase 2
Open to Enrollment
2nd Line (post PD-1)
Multiple
David Portnoy, MD
Merck Sharp & Dohme Corp
Melanoma
An open-label, multicenter, Phase 1/2 study of RP1 as a single agent and in combination with PD1 blockade in patients with solid tumors
VIEW TRIAL ON CLINICALTRIALS.GOVMelanoma, Skin Cancer, ocular melanoma, mucosal melanoma
Stage 4
Phase 2
Open to Enrollment
2nd
RP1 + nivolumab
Oncolytic virus
Ari VanderWalde, MD
Replimune Inc.
Melanoma
A Randomized, Controlled, Phase 3 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment in Patients With Hepatic-Dominant Ocular Melanoma
VIEW TRIAL ON CLINICALTRIALS.GOVMelanoma, Ocular melanoma, hepatic metastases, skin
Stage 4
Phase 3
Open to Enrollment
Metastatic Any Line
Percutaneous hepatic perfusion of melphalan
Percutaneous hepatic perfusion
Evan Glazer, MD
Delcath Systems Inc.
Ocular melanoma
A Phase I/II Study Evaluating the Dosing, Safety, Efficacy, and Biological Activity of Intraperitoneal GEN-1 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered in Combination With Neoadjuvant Chemotherapy (NACT) in Patients Newly Diagnosed With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
VIEW TRIAL ON CLINICALTRIALS.GOVOvarian, fallopian tube, primary peritoneal
Stage 3
Phase 2
Open to Enrollment
Neoadjuvant
GEN-1
IL-12 plasmid formulated with PEG-PEI-Cholesterol Lipopolymer
Adam ElNaggar, MD
Celsion
high grade serous adenocarcinoma, endometrioid adenocarcinoma, undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma, or adenocarcinoma NOS
A phase 2 open-label, single-arm study to evaluate the efficacy and safety of the combination of niraparib and TSR-042 in patients with platinum-resistant ovarian cancer (MOONSTONE)
VIEW TRIAL ON CLINICALTRIALS.GOVOvarian, Primary Peritoneal Cancer, Fallopian Tube
Stage 4
Phase 2
Open to Enrollment
2nd, 3rd, or 4th line
Niraparib and TSR-042
PARP inhibitor and PD-1 antibody
Adam ElNaggar, MD
Tesaro, Inc.
High grade serous, endometrioid, or clear cell
An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Leucovorin Versus Nab-paclitaxel Plus Gemcitabine in Subjects Who Have Not Previously Received Chemotherapy for Metastatic Adenocarcinoma of the Pancreas
VIEW TRIAL ON CLINICALTRIALS.GOVPancreas Adenocarcinoma
Stage 4
Phase 3
Open to Enrollment
1st
Irinotecan liposome injection (Nal-IRI)
Liposomal chemotherapy
Axel Grothey, MD
Ipsen
Adenocarcinoma
A Phase 3, Randomized, Double-Blind Study of Nivolumab or Placebo in Combination With Docetaxel, in Men With Metastatic Castration-resistant Prostate Cancer
VIEW TRIAL ON CLINICALTRIALS.GOVProstate Cancer
Stage 4
Phase 3
Open to Enrollment
1st Line Chemo
Nivolumab
PD-1 inhibitor
Dan Vaena, MD
Bristol-Myers Squibb
Adenocarcinoma
Phase 2 Study of MK-6482 in Participants With Advanced Renal Cell Carcinoma
VIEW TRIAL ON CLINICALTRIALS.GOVRenal cell carcinoma, Kidney cancer, clear cell, RCC
Stage 4
Phase 2
Open to Enrollment
2nd, 3rd, or 4th
Belzutifan
HIF-2a inhibitor
Dan Vaena, MD
Merck Sharp & Dohme Corp
Clear cell component
An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid Tumors
VIEW TRIAL ON CLINICALTRIALS.GOVNon-melanoma skin cancer, basal cell carcinoma, cutaneous squamous cell carcinoma, Merkel cell carcinoma,
Stage 4
Phase 2
Open to Enrollment
No prior PD-1
RP1, nivolumab
oncolytic virus (HSV), PD-1 inhibitor
Ari VanderWalde, MD
Replimune, Inc.
Basal cell carcinoma, cutaneous squamous cell carcinoma, Merkel cell carcinoma, basosquamous carcinoma, high-grade dermatofibroma protuberans, angiosarcoma of the skin, non-HIV-related Kaposi sarcoma, sebaceous gland carcinome, eccrine carcinomas
myTACTIC: An open-label Phase II study evaluating targeted therapies in patients who have advanced solid tumors with genoic alterations or protein expression pattersn predictive of response: Arm A: Entrectinib in patients with ROS1 fusion-positive tumors
VIEW TRIAL ON CLINICALTRIALS.GOVBreast, Colon, Prostate, Small Cell lung, thyroid, head and neck, HNSCC, liver, pancreas, endometrial, cervical, ovarian, skin, melanoma, leukemia, lymphoma, urothelial (bladder), kidney (RCC), myeloma, gastric, small bowel,
Stage 4
Phase 2
Open to Enrollment
Ideally 1st line, but can be later line as well
Entrectinib
TKI against NTRK, ROS, and ALK
Axel Grothey, MD
Genentech, Inc.
ROS1 fusion. Any cancer type except not NSCLC
myTACTIC: An open-label Phase II study evaluating targeted therapies in patients who have advanced solid tumors with genoic alterations or protein expression pattersn predictive of response: ArmB: GDC-0077 in patients with PI3K activating mutation-positive tumors
VIEW TRIAL ON CLINICALTRIALS.GOVBreast, Lung (NSCLC), Colon, Prostate, Small Cell lung, thyroid, head and neck, HNSCC, liver, pancreas, endometrial, cervical, ovarian, skin, melanoma, leukemia, lymphoma, urothelial (bladder), kidney (RCC), myeloma, gastric, small bowel,
Stage 4
Phase 2
Open to Enrollment
Any line
GDC-0077
PI3K p110 alpha inhibitor
Axel Grothey, MD
Genentech, Inc.
PIK3CA mutation positive. Any malignancy except NOT CNS tumors
myTACTIC: An open-label Phase II study evaluating targeted therapies in patients who have advanced solid tumors with genoic alterations or protein expression pattersn predictive of response: ArmC: Alectinib in patients with ALK rearrangement-positive tumors
VIEW TRIAL ON CLINICALTRIALS.GOVBreast, Colon, Prostate, Small Cell lung, thyroid, head and neck, HNSCC, liver, pancreas, endometrial, cervical, ovarian, skin, melanoma, leukemia, lymphoma, urothelial (bladder), kidney (RCC), myeloma, gastric, small bowel,
Stage 4
Phase 2
Open to Enrollment
Any line
Alectinib
ALK and RET inhibitor
Axel Grothey, MD
Genentech, Inc.
ALK rearrangement/fusion in any malignancy except not NSCLC
myTACTIC: An open-label Phase II study evaluating targeted therapies in patients who have advanced solid tumors with genoic alterations or protein expression pattersn predictive of response: Arm D: Ipatasertib in patients with PTEN Loss/Loss-of-function or AKT activating mutation-positive tumors
VIEW TRIAL ON CLINICALTRIALS.GOVAny: Lung, Breast, Colon, Prostate, Small Cell lung, thyroid, head and neck, HNSCC, liver, pancreas, endometrial, cervical, ovarian, skin, melanoma, leukemia, lymphoma, urothelial (bladder), kidney (RCC), myeloma, gastric, small bowel,
Stage 4
Phase 2
Open to Enrollment
Any line
Ipatasertib
AKT inhibitor
Axel Grothey, MD
Genentech, Inc.
PTEN loss or loss of function
myTACTIC: An open-label Phase II study evaluating targeted therapies in patients who have advanced solid tumors with genoic alterations or protein expression pattersn predictive of response: Arm D: Ipatasertib in patients with PTEN Loss/Loss-of-function or AKT activating mutation-positive tumors
VIEW TRIAL ON CLINICALTRIALS.GOVAny: Lung, Breast, Colon, Prostate, Small Cell lung, thyroid, head and neck, HNSCC, liver, pancreas, endometrial, cervical, ovarian, skin, melanoma, leukemia, lymphoma, urothelial (bladder), kidney (RCC), myeloma, gastric, small bowel,
Stage 4
Phase 2
Open to Enrollment
Any line
Ipatasertib
AKT inhibitor
Axel Grothey, MD
Genentech, Inc.
select AKT mutations
myTACTIC: An open-label Phase II study evaluating targeted therapies in patients who have advanced solid tumors with genoic alterations or protein expression patterns predictive of response: Atezolizumab plus chemotherapy in patients with TMB-H/MSI-H/dMMR-positive tumors
VIEW TRIAL ON CLINICALTRIALS.GOVAny: Lung, Breast, Colon, Prostate, Small Cell lung, thyroid, head and neck, HNSCC, liver, pancreas, endometrial, cervical, ovarian, skin, melanoma, leukemia, lymphoma, urothelial (bladder), kidney (RCC), myeloma, gastric, small bowel,
Stage 4
Phase 2
Open to Enrollment
Any line but cannot have previously had PD-1
Atezoliumab + chemotherapy (investigators choice- capecitabine, paclitaxel, or docetaxel)
PD-L1 inhibitor + chemotherapy
Axel Grothey, MD
Genentech, Inc.
TMB high, defined as > or = 10 mutations/megabase
myTACTIC: An open-label Phase II study evaluating targeted therapies in patients who have advanced solid tumors with genoic alterations or protein expression patterns predictive of response: Atezolizumab plus chemotherapy in patients with TMB-H/MSI-H/dMMR-positive tumors
VIEW TRIAL ON CLINICALTRIALS.GOVAny: Lung, Breast, Colon, Prostate, Small Cell lung, thyroid, head and neck, HNSCC, liver, pancreas, endometrial, cervical, ovarian, skin, melanoma, leukemia, lymphoma, urothelial (bladder), kidney (RCC), myeloma, gastric, small bowel,
Stage 4
Phase 2
Open to Enrollment
Any, but cannot have had prior anti-PD-1 or anti-PD-L1
Atezoliumab + chemotherapy (investigators choice- capecitabine, paclitaxel, or docetaxel)
PD-L1 inhibitor + chemotherapy
Axel Grothey, MD
Genentech, Inc.
MSI-h or dMMR
myTACTIC: An open-label Phase II study evaluating targeted therapies in patients who have advanced solid tumors with genomic alterations or protein expression patterns predictive of response: Arm F: Trastuzumab emtansine plus atezolizumab Arm G: PH FDC SC Arm H: PH FDC SC plus chemotherapy Arm I: trastuzumab emtansine plus tucatinib, in patients with ERBB2 gene amplification- or mutation-positive tumors.
VIEW TRIAL ON CLINICALTRIALS.GOVLung, Colon, Prostate, Small Cell lung, thyroid, head and neck, HNSCC, liver, pancreas, endometrial, cervical, ovarian, skin, melanoma, leukemia, lymphoma, urothelial (bladder), kidney (RCC), myeloma, gastric, small bowel,
Stage 4
Phase 2
Open to Enrollment
Any, but cannot have had prior
TDM-1 with atezolizumab, or PH FDC SC with or without chemotherapy, or TDM-1 with tucatinib
Anti-HER2 agents
Axel Grothey, MD
Genentech, Inc.
ERBB2 amplification or specific mutation
myTACTIC: An open-label Phase II study evaluating targeted therapies in patients who have advanced solid tumors with genomic alterations or protein expression patterns predictive of response: Arm J: Trastuzumab emtansine plus atezolizumab in patients with ERBB2 amplification or mutation plus TMB-H/MSI-H/dMMR-positive tumors
VIEW TRIAL ON CLINICALTRIALS.GOVLung, Colon, Prostate, Small Cell lung, thyroid, head and neck, HNSCC, liver, pancreas, endometrial, cervical, ovarian, skin, melanoma, leukemia, lymphoma, urothelial (bladder), kidney (RCC), myeloma, gastric, small bowel,
Stage 4
Phase 2
Open to Enrollment
Any line
TD-M1 + atezolizumab
anti-HER2 agent and anti-PD-L1 agent
Axel Grothey, MD
Genentech, Inc.
ERBB amplificaiton or mutation AND TMB-h or MSI-h or dMMR
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)
VIEW TRIAL ON CLINICALTRIALS.GOVSolid Tumors: Breast, Lung (NSCLC), Colon, Prostate, Bladder, Kidney, Esophagus, Stomach (Gastric), Liver (HCC), Cervical, Endometrial, Ovarian, Skin, Head and Neck (SCCHN), Bladder, Kidney (renal cell), Pancreatic, Rectal, Brain (GBM, glioblastoma)
Stage 4
Phase 2
Open to Enrollment
Following all effecive therapy (late line)
Pemigatinib
FGFR inhibitor
Dan Vaena, MD
Incyte Corporation
FGFR 1,2,3 mutated or FGFR 1,2,3 fusion/translocation
An open-label, multicenter, multinational, phase 2 study exploring the efficacy and safety of neratinib therapy in patients with solid tumors with activating HER2, HER3 or EGFR mutations or with EGFR gene amplification
VIEW TRIAL ON CLINICALTRIALS.GOVBladder, Breast, Brain (GBM), Head and Neck, Prostate, Kidney (Renal Cell), Melanoma, Ovarian, Endometrial (Uterine), Cervical, Gastric, Pancreatic, Hepatocellular (HCC), Esophageal, lymphoma, sarcoma
Stage 4
Phase 2
Open to Enrollment
Any (provided no curative therapy available)
Neratinib
pan-HER TKI
Lee Schwartzberg, MD
Puma Biotechnologies
HER2 (ERBB2) mutation or HER4 (ERBB4 mutation), or EGFR ex. 18 mutated lung cancer
A Phase 1/2 Study of Relatlimab (Anti-LAG-3 Monoclonal Antibody) Administered in Combination With Both Nivolumab (Anti-PD-1 Monoclonal Antibody) and BMS-986205 (IDO1 Inhibitor) or in Combination With Both Nivolumab and Ipilimumab (Anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors
VIEW TRIAL ON CLINICALTRIALS.GOVPart 2A: Melanoma, Head and Neck. Part 2B: NSCLC (lung)
Stage 4
Phase 1
Open to Enrollment
1st Line
Relatlimab with nivolumab and ipilimumab or relatlimab with nivolumab and BMS-986205)
LAG-3 inhibitor with PD-1 inhibitor and either CTLA-4 inhibitor or IDO inhibitor
Ari VanderWalde
Bristol-Myers Squibb
Selected solid tumor types
Part 1:
A Phase I/II, Open-Label, Dose Escalation and Cohort Expansion Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of OBI-888 in Patients With Locally Advanced or Metastatic Solid Tumors.
VIEW TRIAL ON CLINICALTRIALS.GOVColon, Ovarian, Gastric, Pancreatic, Endometrial, lung, prostate, breast
Stage 4
Phase 1
Open to Enrollment
Late line
OBI-888
Anti-globo-H antibody
Axel Grothey, MD
OBI Pharma
Globo-H overexpression
A Phase 1b/2, Multicenter, Open-Label Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors Nivolumab or Pembrolizumab in Adult Patients With Advanced Solid Tumors
VIEW TRIAL ON CLINICALTRIALS.GOVUrothelial Neoplasm, Bladder Cancer, Renal Cell Carcinoma, Head and Neck, Lung Cancer, NSCLC, Ovarian Cancer, Gastric Cancer, Esophageal Cancer, Colorectal Cancer, Cervical Cancer, Melanoma
Stage 4
Phase 1
Open to Enrollment
1st or later
DSP-7888
peptide vaccine stimulating cytotoxic T-cells expressing WT1
Dan Vaena, MD
Sumitomo Dainippon Pharma Oncology Inc.
Carcinoma
A Phase 1/2a, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of PEN-866 in Patients With Advanced Solid Malignancies
VIEW TRIAL ON CLINICALTRIALS.GOVAnal cancer, Pancreatic cancer, PDAC, Cervix, cervical cancer, Gastric cancer, Gastroesophageal cancer, SCLC, Small cell lung cancer, penile, vulvar
Stage 4
Phase 1
Open to Enrollment
2nd or later
PEN-866
HSP-90 inhibitor
Dan Vaena, MD
Tarveda Therapeutics
adenocarcinoma or squamous cell carcinoma
Phase 1/1b Study of the Safety of TTX-030 as a Single Agent and in Combination With Pembrolizumab or Chemotherapy in Patients With Lymphoma or Solid Tumor Malignancies
VIEW TRIAL ON CLINICALTRIALS.GOVLung, Breast, Colon, Pancreas, Bladder, Kidney, Prostate, Melanoma, Lymphoma, Gastric, Head and Neck (SCCHN)
Stage 4
Phase 1
Open to Enrollment
Any line as long as appropriate to give study acceptable chemo in combination
TTX-030
anti CD-39
Dan Vaena, MD
Trishula Therapeutics, Inc.
Any malignancy
Phase 1/1b Study to Evaluate the Safety and Activity of TTX-030 (Anti-CD39) in Combination With Budigalimab and/or Chemotherapy in Subjects With Advanced Solid Tumors
VIEW TRIAL ON CLINICALTRIALS.GOVProstate, Kidney, Head and Neck, Colon Rectum, Gastric, Esophagus
Stage 4
Phase 1
Open to Enrollment
late line
TTX-030, budigalimab
Anti CD-39, anti-PD1
Dan Vaena, MD
Tizona Therapeutics
Any
A Phase 1/2 Study of BMS-986315 as Monotherapy and in Combination with Nivolumab or
Cetuximab in Participants with Advanced Solid Tumors
Advanced Solid Tumors, renal cell, head and neck cancer (SCCHN), non-small cell lung cancer (NSCLC)
Stage 4
Phase 1
Open to Enrollment
> or = 2nd line
BMS-986315 with either nivolumab or cetuximab
NKG2A inhibitor
Dan Vaena, MD
Bristol-Myers Squibb
A Phase 1a/1b study of COM701 as monotherapy and in combination with an anti-PD-1 antibody in subjects with advanced solid tumors.
VIEW TRIAL ON CLINICALTRIALS.GOVOvarian, uterine, endometrial, breast, TNBC, lung, colon, CRC, NSCLC, head and neck, SCCHN, gastric, stomach, kidney, renal, RCC, bladder, transitional cell,
Stage 4
Phase 1
Open to Enrollment
Late line
COM-701, PD(L)-1 antibody
PVRIG monoclonal antibody, PD(L)-1 antibody
Dan Vaena, MD
Compugen
A Phase 1/2 first-in-human study of BMS-986258 alone and in combination with nivolumab in advanced malignant tumors
VIEW TRIAL ON CLINICALTRIALS.GOVRenal cell (kidney), CRC (colon, rectal, colorectal), lung cancer (NSCLC), Head and Neck (SCCHN), Triple Negative Breast (TNBC)
Stage 4
Phase 1
Open to Enrollment
2nd line or greater
BMS 986258
TIM-3 antibody
Dan Vaena, MD
Bristol Myers Squibb
Lung- non-small cell; Breast- Triple Negative; RCC- clear cell; CRC- any; SCCHN- any